S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:NTLA

Intellia Therapeutics Competitors

$51.81
-2.61 (-4.80 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.86
Now: $51.81
$55.34
50-Day Range
$54.42
MA: $68.87
$83.68
52-Week Range
$9.18
Now: $51.81
$92.00
Volume3.21 million shs
Average Volume1.77 million shs
Market Capitalization$3.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.09

Competitors

Intellia Therapeutics (NASDAQ:NTLA) Vs. QDEL, NEOG, RIOT, MYGN, HSKA, and LNTH

Should you be buying NTLA stock or one of its competitors? Companies in the industry of "diagnostic substances" are considered alternatives and competitors to Intellia Therapeutics, including Quidel (QDEL), Neogen (NEOG), Riot Blockchain (RIOT), Myriad Genetics (MYGN), Heska (HSKA), and Lantheus (LNTH).

Quidel (NASDAQ:QDEL) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Quidel and Intellia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
Intellia Therapeutics-193.01%-40.14%-30.11%

Valuation and Earnings

This table compares Quidel and Intellia Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million11.97$72.92 million$2.7355.42
Intellia Therapeutics$43.10 million81.41$-99,530,000.00($2.11)-24.55

Quidel has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Quidel has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

84.0% of Quidel shares are owned by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are owned by institutional investors. 14.1% of Quidel shares are owned by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Quidel and Intellia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel11302.40
Intellia Therapeutics051002.67

Quidel currently has a consensus price target of $245.60, indicating a potential upside of 62.33%. Intellia Therapeutics has a consensus price target of $56.6154, indicating a potential upside of 9.28%. Given Quidel's higher probable upside, research analysts clearly believe Quidel is more favorable than Intellia Therapeutics.

Summary

Quidel beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.

Neogen (NASDAQ:NEOG) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Profitability

This table compares Neogen and Intellia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neogen13.92%8.13%7.45%
Intellia Therapeutics-193.01%-40.14%-30.11%

Valuation and Earnings

This table compares Neogen and Intellia Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neogen$418.17 million10.15$59.47 million$1.1370.58
Intellia Therapeutics$43.10 million81.41$-99,530,000.00($2.11)-24.55

Neogen has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Neogen has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

92.8% of Neogen shares are owned by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are owned by institutional investors. 0.9% of Neogen shares are owned by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Neogen and Intellia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neogen02102.33
Intellia Therapeutics051002.67

Neogen currently has a consensus price target of $81.50, indicating a potential upside of 2.19%. Intellia Therapeutics has a consensus price target of $56.6154, indicating a potential upside of 9.28%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Neogen.

Riot Blockchain (NASDAQ:RIOT) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.

Valuation and Earnings

This table compares Riot Blockchain and Intellia Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Riot Blockchain$6.84 million397.87$-20,040,000.00($0.73)-55.21
Intellia Therapeutics$43.10 million81.41$-99,530,000.00($2.11)-24.55

Riot Blockchain has higher earnings, but lower revenue than Intellia Therapeutics. Riot Blockchain is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Riot Blockchain has a beta of 4.56, meaning that its share price is 356% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Riot Blockchain and Intellia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Riot Blockchain00103.00
Intellia Therapeutics051002.67

Riot Blockchain currently has a consensus price target of $28.00, indicating a potential downside of 30.52%. Intellia Therapeutics has a consensus price target of $56.6154, indicating a potential upside of 9.28%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Riot Blockchain.

Profitability

This table compares Riot Blockchain and Intellia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Riot Blockchain-250.06%-51.38%-47.50%
Intellia Therapeutics-193.01%-40.14%-30.11%

Institutional and Insider Ownership

9.0% of Riot Blockchain shares are owned by institutional investors. Comparatively, 95.6% of Intellia Therapeutics shares are owned by institutional investors. 3.5% of Riot Blockchain shares are owned by insiders. Comparatively, 4.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Intellia Therapeutics beats Riot Blockchain on 9 of the 14 factors compared between the two stocks.

Intellia Therapeutics (NASDAQ:NTLA) and Myriad Genetics (NASDAQ:MYGN) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Valuation & Earnings

This table compares Intellia Therapeutics and Myriad Genetics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$43.10 million81.41$-99,530,000.00($2.11)-24.55
Myriad Genetics$638.60 million3.28$-199,500,000.00($0.35)-79.54

Intellia Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intellia Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Intellia Therapeutics and Myriad Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellia Therapeutics051002.67
Myriad Genetics33001.50

Intellia Therapeutics presently has a consensus target price of $56.6154, indicating a potential upside of 9.28%. Myriad Genetics has a consensus target price of $17.20, indicating a potential downside of 38.22%. Given Intellia Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Myriad Genetics.

Profitability

This table compares Intellia Therapeutics and Myriad Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellia Therapeutics-193.01%-40.14%-30.11%
Myriad Genetics-32.49%-4.07%-2.68%

Institutional and Insider Ownership

95.6% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Myriad Genetics shares are owned by institutional investors. 4.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 2.8% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Intellia Therapeutics (NASDAQ:NTLA) and Heska (NASDAQ:HSKA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Valuation & Earnings

This table compares Intellia Therapeutics and Heska's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$43.10 million81.41$-99,530,000.00($2.11)-24.55
Heska$122.66 million13.26$-1,470,000.00$0.053,433.60

Heska has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intellia Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Heska has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Intellia Therapeutics and Heska, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellia Therapeutics051002.67
Heska01402.80

Intellia Therapeutics presently has a consensus target price of $56.6154, indicating a potential upside of 9.28%. Heska has a consensus target price of $185.80, indicating a potential upside of 8.22%. Given Intellia Therapeutics' higher possible upside, equities analysts plainly believe Intellia Therapeutics is more favorable than Heska.

Profitability

This table compares Intellia Therapeutics and Heska's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellia Therapeutics-193.01%-40.14%-30.11%
Heska-11.15%-2.29%-1.64%

Institutional and Insider Ownership

95.6% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Heska shares are owned by institutional investors. 4.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 11.7% of Heska shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Heska beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.

Intellia Therapeutics (NASDAQ:NTLA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Valuation & Earnings

This table compares Intellia Therapeutics and Lantheus' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$43.10 million81.41$-99,530,000.00($2.11)-24.55
Lantheus$347.34 million3.67$31.67 million$1.1716.29

Lantheus has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Intellia Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Intellia Therapeutics and Lantheus, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellia Therapeutics051002.67
Lantheus01302.75

Intellia Therapeutics presently has a consensus target price of $56.6154, indicating a potential upside of 9.28%. Lantheus has a consensus target price of $23.6667, indicating a potential upside of 24.17%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Intellia Therapeutics.

Profitability

This table compares Intellia Therapeutics and Lantheus' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellia Therapeutics-193.01%-40.14%-30.11%
Lantheus0.12%11.05%5.43%

Institutional and Insider Ownership

95.6% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 85.0% of Lantheus shares are owned by institutional investors. 4.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 2.1% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lantheus beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.


Intellia Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Quidel logo
QDEL
Quidel
2.4$151.30-2.2%$6.40 billion$534.89 million17.76Analyst Revision
Neogen logo
NEOG
Neogen
1.2$79.75-2.6%$4.25 billion$418.17 million69.96News Coverage
Riot Blockchain logo
RIOT
Riot Blockchain
0.9$40.30-9.9%$2.72 billion$6.84 million-67.17Analyst Downgrade
Decrease in Short Interest
Gap Down
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.84-2.1%$2.09 billion$638.60 million-10.71Analyst Report
Decrease in Short Interest
Gap Down
Heska logo
HSKA
Heska
1.2$171.68-2.8%$1.63 billion$122.66 million-77.33Analyst Report
High Trading Volume
Gap Up
Lantheus logo
LNTH
Lantheus
1.7$19.06-3.0%$1.28 billion$347.34 million238.28Analyst Downgrade
Gap Up
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$26.21-3.9%$1.04 billion$3.57 million-11.75News Coverage
Gap Up
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$21.91-3.8%$945.31 million$253.67 million20.29Analyst Report
Gap Up
Aspira Women's Health logo
AWH
Aspira Women's Health
1.5$6.72-1.2%$702.80 million$4.54 million-44.77
Oxford Immunotec Global logo
OXFD
Oxford Immunotec Global
1.1$21.99-0.0%$570.90 million$73.71 million-32.82Upcoming Earnings
News Coverage
Quotient logo
QTNT
Quotient
1.6$3.79-3.2%$383.29 million$32.66 million-3.21Gap Down
Nymox Pharmaceutical logo
NYMX
Nymox Pharmaceutical
0.7$2.43-2.5%$187.62 million$120,000.00-13.50Gap Down
Trinity Biotech logo
TRIB
Trinity Biotech
0.5$4.16-7.5%$86.95 million$90.43 million-7.17News Coverage
Gap Down
ICCC
ImmuCell
1.3$9.08-3.0%$65.49 million$13.72 million-39.48Gap Down
Biomerica logo
BMRA
Biomerica
1.3$5.50-6.2%$64.79 million$6.69 million-13.75Gap Down
ABIO
ARCA biopharma
0.9$4.12-3.4%$38.40 millionN/A-1.60Upcoming Earnings
Increase in Short Interest
Gap Up
Achieve Life Sciences logo
ACHV
Achieve Life Sciences
1.5$10.59-1.4%$38.32 millionN/A-0.96Upcoming Earnings
News Coverage
AKER
Akers Biosciences
0.7$2.75-4.0%$24.37 million$1.58 million0.00Increase in Short Interest
Gap Up
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.